cRGD-modified hybrid lipopolymeric nanoplexes for gene editing in the posterior segment of the eye
Deepak Kumar Sahel,Sangam Giri Goswami,Reena Jatyan,Abhay Tharmatt,Vivek Singh,Manu Dalela,Sujata Mohanty,Anupama Mittal,Sivaprakash Ramalingam,Deepak Chitkara
DOI: https://doi.org/10.1016/j.ijbiomac.2024.132426
IF: 8.2
2024-06-01
International Journal of Biological Macromolecules
Abstract:Eye-related diseases, specifically retinal dystrophy (RD) conditions, are the leading cause of blindness worldwide. Gene addition, regulation, or editing could potentially treat such diseases through gene expression regulation. CRISPR/Cas9 gene editing is one of the most prominent and precise gene editing tools which could be employed to edit genes related to the dystrophic condition. However, CRISPR/Cas9 faces in vivo delivery challenges due to its high molecular weight, negative charge, prone to degradation in the presence of nucleases and proteases, poor cellular degradation, etc. , which makes it challenging to adopt for therapeutic applications. We developed cRGD-modified lipopolymeric nanoplexes loaded with Cas9 RNPs with a particle size and zeta potential of 175 ± 20 nm and 2.15 ± 0.9 mV, respectively. The cRGD-modified lipopolymeric nanoplexes were stable for 194 h and able to transfect >70 % ARPE-19 and NIH3T3 cells with an Indel frequency of ~40 % for the VEGF-A gene. The cRGD-modified lipopolymeric nanoplexes found good vitreous mobility and could transfection retinal cells in vivo after 48 h of intravitreal injection in Wistar Rats. Moreover, in vivo VEGFA gene editing was ~10 % with minimal toxicities. Collectively, the cRGD-modified lipopolymeric nanoplexes were found to have extreme potential in delivering CRISPR/Cas9 RNPs payload to the retinal tissues for therapeutic applications.
polymer science,biochemistry & molecular biology,chemistry, applied